{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=82",
    "query": {
      "condition": "Plasma",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 3601,
    "total_pages": 361,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:42:43.384Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02181413",
      "title": "A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Autologous Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "Ixazomib Citrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 656,
      "start_date": "2014-07-16",
      "completion_date": "2023-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02181413"
    },
    {
      "nct_id": "NCT07075185",
      "title": "A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Myeloma Multiple",
        "Multiple Myeloma Progression",
        "Neoplasms by Histologic Type",
        "Neoplasm",
        "Hemostatic Disorders",
        "Vascular Disorder",
        "Paraproteinemias",
        "Blood Protein Disorders",
        "Hematologic Disease and Disorders",
        "Lymphoproliferative Disorders",
        "Immunoproliferative Disorders",
        "Immune System Disease",
        "Gene Therapy"
      ],
      "interventions": [
        {
          "name": "KLN-1010",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kelonia Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-07-16",
      "completion_date": "2042-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07075185"
    },
    {
      "nct_id": "NCT02115035",
      "title": "A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Vermurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2014-08-27",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02115035"
    },
    {
      "nct_id": "NCT00724568",
      "title": "Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2008-05",
      "completion_date": "2014-09-03",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00724568"
    },
    {
      "nct_id": "NCT00353860",
      "title": "Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunosuppression",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "SOLEX 300i Stem Cell Selection",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "10 Years to 80 Years"
      },
      "enrollment_count": 70,
      "start_date": "2002-01-23",
      "completion_date": "2007-11-29",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00353860"
    },
    {
      "nct_id": "NCT04876248",
      "title": "Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Belantamab Mafodotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-08-19",
      "completion_date": "2027-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04876248"
    },
    {
      "nct_id": "NCT02952508",
      "title": "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinemia",
        "Multiple Myeloma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Marginal Zone Lymphoma",
        "Mantle Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iopofosine I 131 single dose",
          "type": "DRUG"
        },
        {
          "name": "Iopofosine I 131 multiple dose",
          "type": "DRUG"
        },
        {
          "name": "Iopofosine I 131 fractionated dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellectar Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2017-07-26",
      "completion_date": "2027-12-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952508"
    },
    {
      "nct_id": "NCT00585676",
      "title": "Impact of Antenatal Betamethasone on Plasma Glucose Levels",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2007-11",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585676"
    },
    {
      "nct_id": "NCT03262389",
      "title": "Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Fludeoxyglucose PET CT",
          "type": "DRUG"
        },
        {
          "name": "Sodium Acetate C11 PET CT",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose PET MRI",
          "type": "DRUG"
        },
        {
          "name": "Sodium Acetate C11 PET MRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael C Roarke, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-09-19",
      "completion_date": "2019-11-23",
      "has_results": true,
      "last_update_posted_date": "2021-03-16",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03262389"
    },
    {
      "nct_id": "NCT04743674",
      "title": "Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2024-05-03",
      "completion_date": "2027-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-11-19T10:42:43.384Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743674"
    }
  ]
}